<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04307277</url>
  </required_header>
  <id_info>
    <org_study_id>19SARC05</org_study_id>
    <nct_id>NCT04307277</nct_id>
  </id_info>
  <brief_title>Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Grade 1 or 2 Soft Tissue Sarcoma</brief_title>
  <acronym>CHIC-STS01</acronym>
  <official_title>Interest of Peri Operative CHemotherapy In Patients With CINSARC High-risk Localized Grade 1 or 2 Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III, multicenter, randomized open-label and comparative study designed to demonstrate&#xD;
      whether adding 4 cycles of peri-operative doxorubicin-based chemotherapy improves&#xD;
      metastasis-free survival as compared with standard management in patients with resectable&#xD;
      FNCLCC grade 1/2 STS, considered as high-risk according to CINSARC (Complexity Index in&#xD;
      SARComas) signature.&#xD;
&#xD;
      After signed informed consent, patients considered as eligible to CHIC-STS study by the&#xD;
      investigator will be enrolled in the study and a molecular screening will be performed (600&#xD;
      patients will be screened).&#xD;
&#xD;
      Patients considered as low-risk according to CINSARC signature will be treated at the&#xD;
      discretion of the clinicians (prospective cohort).&#xD;
&#xD;
      Patients considered as high-risk according to CINSARC signature will be randomized in the&#xD;
      open-label multicenter phase III trial and assigned in one of the two following treatments&#xD;
      arms:&#xD;
&#xD;
        -  Arm A (control arm): Standard of care (surgical excision +/- external radiotherapy).&#xD;
&#xD;
        -  Arm B (experimental arm): Standard of care + 4 cycles of intravenous chemotherapy during&#xD;
           12 weeks.&#xD;
&#xD;
      A total of 250 patients will have to be randomized with 125 patients in each arm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2020</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metastasis-free survival defined by the delay between randomization and the appearance of metastatic.</measure>
    <time_frame>5 years for each patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival defined by the delay between randomization and first relapse (local, regional, or distant) or death from any cause.</measure>
    <time_frame>5 years for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by the toxicity grading of the National Cancer Institute (NCI-CTCAE v5.0).</measure>
    <time_frame>4 months for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival defined by the delay between randomization and death from any cause.</measure>
    <time_frame>5 years for each patient</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care + chemotherapy</intervention_name>
    <description>Doxorubicine with Ifosfamide during 4 cycles Q3W Or Doxorubicine with Dacarbazine during 4 cycles Q3W (for patients with Leiomyosarcoma)</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Surgical excision with external radiotherapy (if applicable)</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of soft-tissue sarcoma, histologically confirmed by RRePS (Réseau de&#xD;
             Référence en Pathologie des Sarcomes et des Viscères) network.&#xD;
&#xD;
          2. According to FNCLCC grading system, grade 2 and grade 1 tumors.&#xD;
&#xD;
          3. Resectable and localized disease after appropriate extension work-up (including at&#xD;
             least a chest-CT).&#xD;
&#xD;
          4. Available archived FFPE tumor sample in sufficient quantity to allow CINSARC&#xD;
             qualification.&#xD;
&#xD;
          5. Age ≥ 18 years.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.&#xD;
&#xD;
          7. Life expectancy of at least 12 weeks after the start of the treatment.&#xD;
&#xD;
          8. Women should be post-menopaused or willing to accept the use of an effective&#xD;
             contraceptive regimen during the treatment period and at least 12 months after the end&#xD;
             of the treatment period. All non-menopaused women should have a negative pregnancy&#xD;
             test within 72 hours prior to registration.&#xD;
&#xD;
          9. Signed written informed consent.&#xD;
&#xD;
         10. Patient affiliated to a Social Health Insurance in France.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Soft-tissue sarcoma with the following histological subtypes: well-differentiated&#xD;
             liposarcomas, alveolar soft-part sarcoma, dermatofibrosarcoma protuberans, clear-cell&#xD;
             sarcoma, epithelioid sarcoma, alveolar or embryonal rhabdomyosarcoma.&#xD;
&#xD;
          2. Primitive cutaneous, retroperitoneal, uterus or visceral STS.&#xD;
&#xD;
          3. Metastatic disease.&#xD;
&#xD;
          4. Previous or ongoing treatment for the sarcoma (with the exception of a surgery for&#xD;
             diagnosis intend).&#xD;
&#xD;
          5. Contra-indication for Doxorubicin, Ifosfamide and Dacarbazine treatments.&#xD;
&#xD;
          6. Prior therapy with ifosfamide or cyclophosphamide or other nitrogen mustards, and&#xD;
             prior therapy with anthracyclines.&#xD;
&#xD;
          7. Prior mediastinal/cardiac radiotherapy.&#xD;
&#xD;
          8. History or presence of clinically relevant cardiovascular abnormalities such as&#xD;
             uncontrolled hypertension, congestive heart failure NYHA classification of 3, unstable&#xD;
             angina or poorly controlled arrhythmia, myocardial infarction within 6 months prior to&#xD;
             study entry.&#xD;
&#xD;
          9. Prior or concurrent malignant disease diagnosed or treated in the last 2 years except&#xD;
             for adequately treated in situ carcinoma of the cervix, basal or squamous skin cell&#xD;
             carcinoma, or in situ transitional bladder cell carcinoma.&#xD;
&#xD;
         10. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic&#xD;
             therapy.&#xD;
&#xD;
         11. Known infection with HIV, hepatitis B, or hepatitis C.&#xD;
&#xD;
         12. Women who are breastfeeding, pregnant or who plan to become pregnant while in the&#xD;
             trial.&#xD;
&#xD;
         13. Concomitant disease or condition that could interfere with the conduct of the study,&#xD;
             or that would, in the opinion of the investigator, pose an unacceptable risk to the&#xD;
             subject in this study.&#xD;
&#xD;
         14. Patient who has forfeited his/her freedom by administrative or legal award or who is&#xD;
             under legal protection (curatorship and guardianship, protection of justice).&#xD;
&#xD;
         15. Patient unable to comply with the protocol for any reason.&#xD;
&#xD;
        ADDITIONAL CRITERIA FOR THE RANDOMIZED PHASE III STUDY&#xD;
&#xD;
          1. High-risk CINSARC signature.&#xD;
&#xD;
          2. External radiotherapy not initiated before randomization (if applicable).&#xD;
&#xD;
          3. Acceptable hematologic function (within 72 hours of eligibility assessment): Absolute&#xD;
             neutrophil count (ANC) ≥ 1.5 G/L, Platelet count ≥ 100 G/L and Hemoglobin &gt; 9g/dL.&#xD;
&#xD;
          4. Acceptable renal function within 72 hours of eligibility assessment: Serum creatinine&#xD;
             ≤ 1.5 x ULN or calculated creatinine clearance ≥ 60 mL/min (by the Cockcroft and Gault&#xD;
             formula).&#xD;
&#xD;
          5. Acceptable liver function: Bilirubin ≤ 1.5 x upper limit of normal (ULN), AST (SGOT)&#xD;
             and ALT (SGPT) ≤ 2.5 x ULN.&#xD;
&#xD;
          6. Normal LVEF (&gt;50%) measured by echocardiography or isotopic ventriculography .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thibaud VALENTIN</last_name>
    <phone>05 31 15 51 70</phone>
    <email>valentin.thibaud@iuct-oncopole.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loïc CHAIGNEAU</last_name>
      <phone>03 81 47 99 99</phone>
      <email>lchaigneau@chu-besancon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine ITALIANO</last_name>
      <phone>05 56 33 32 44</phone>
      <email>a.italiano@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoé NEVIERE</last_name>
      <phone>02 31 45 50 11</phone>
      <email>z.neviere@baclesse.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale DUBRAY-LONGERAS</last_name>
      <phone>04 73 27 80 80</phone>
      <email>pascale.dubray-longeras@clermont.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges-François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice HERVIEU</last_name>
      <phone>03 80 73 75 06</phone>
      <email>ahervieu@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathieu LARAMAS</last_name>
      <phone>04 76 76 38 42</phone>
      <email>mlaramas@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie LE BRUN-LY</last_name>
      <phone>05 55 05 63 96</phone>
      <email>valerie.lebrun@chu-limoges.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armelle DUFRESNE</last_name>
      <phone>04 69 85 61 46</phone>
      <email>armelle.dufresne@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François BERTUCCI</last_name>
      <phone>04 91 22 35 37</phone>
      <email>bertuccif@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence DUFFAUD</last_name>
      <phone>04 91 38 54 39</phone>
      <email>florence.duffaud@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelly FIRMIN</last_name>
      <phone>04 67 61 45 65</phone>
      <email>nelly.firmin@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esma SAADA-BOUZID</last_name>
      <phone>04 92 03 15 14</phone>
      <email>esma.saada-bouzid@nice.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascaline BOUDOU-ROUQUETTE</last_name>
      <phone>01 58 41 17 46</phone>
      <email>pascaline.boudou@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas ISAMBERT</last_name>
      <phone>05 49 44 45 38</phone>
      <email>nicolas.isambert@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Godinot</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline SOIBINET-OUDOT</last_name>
      <phone>03 26 50 43 83</phone>
      <email>pauline.soibinet@reims.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angélique BRUNOT</last_name>
      <phone>02 99 25 32 80</phone>
      <email>a.brunot@rennes.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile GUILLEMET</last_name>
      <phone>02 32 08 22 37</phone>
      <email>cecile.guillemet@chb.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Saint-Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle BOMPAS</last_name>
      <phone>02 40 67 99 39</phone>
      <email>emmanuelle.bompas@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier COLLARD</last_name>
      <phone>04 77 91 61 55</phone>
      <email>olivier.collard@icloire.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Strasbourg Europe</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justine GANTZER</last_name>
      <phone>03 88 11 51 41</phone>
      <email>j.gantzer@icans.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thibaud VALENTIN</last_name>
      <phone>05 31 15 51 70</phone>
      <email>valentin.thibaud@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine - Centre Alexis Vautrin</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria RIOS</last_name>
      <phone>03 83 59 84 61</phone>
      <email>m.rios@nancy.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2020</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Soft Tissue Sarcoma</keyword>
  <keyword>CINSARC signature</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

